Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.32 |
| ▸ | ITGAV | P06756 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2659662 | 0.92 | ITGB3 (0.32) | LMNATP53THRBITGB3ITGA2B | |
| SCHEMBL2661566 | 0.91 | ITGB3 (0.33) | LMNATP53THRBITGB3ITGA2B | |
| SCHEMBL2660001 | 0.88 | ITGB3 (0.34) | LMNATP53THRBITGB3ITGA2B | |
| SCHEMBL2659937 | 0.88 | ITGB3 (0.33) | LMNATP53THRBITGB3ITGA2B | |
| SCHEMBL2660035 | 0.85 | ITGB3 (0.33) | LMNATP53THRBITGB3ITGA2B | |
| SCHEMBL2660657 | 0.81 | ITGB3 (0.31) | LMNATP53ITGB3ITGA2BITGAV | |
| SCHEMBL2660810 | 0.81 | ITGB3 (0.34) | LMNATP53THRBITGB3ITGA2B | |
| SCHEMBL2660815 | 0.81 | ITGB3 (0.35) | LMNATP53THRBITGB3ITGA2B | |
| SCHEMBL2659893 | 0.80 | SLC40A1 (0.35) | LMNATP53THRBITGB3ITGA2B | |
| SCHEMBL2661568 | 0.80 | ITGB3 (0.32) | ITGB3ITGA2BITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074119-A1 | INDOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008050821-A1 | INDOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |